Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based company said ...

Running her second campaign for Congress, Rebecca Cooke has raised more than $5.3 million through the final reporting period, ...

There isn’t a ton of ISP competition in Madison. Most residents will be weighing the decision between AT&T Fiber or Spectrum cable. Spectrum has some tempting introductory deals, while AT&T’s ...

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test ...

Exact Sciences presents multiple studies at ACG 2024; demonstrating leadership in noninvasive colorectal cancer screening and patient engagement: Madison, Wisconsin Tuesday, Octob ...

especially in underserved populations MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated benefit and burden ...